Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{dbe259f99d8f4e73b9b772cc8353b3a6,
title = "Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial",
abstract = "AIMS: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes.METHODS AND RESULTS: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45{\%}) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6{\%} vs. 35.4 ± 9.4{\%}). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95{\%} confidence interval) was -0.8{\%} (-2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10{\%}) patients treated with liraglutide compared with 3 (3{\%}) patients in the placebo group (P = 0.04).CONCLUSION: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.",
author = "Anders Jorsal and Caroline Kistorp and Pernille Holmager and Tougaard, {Rasmus Stilling} and Roni Nielsen and Anja H{\"a}nselmann and Brian Nilsson and M{\o}ller, {Jacob Eifer} and Jakob Hjort and Rasmussen, {Jon B.} and Boesgaard, {Trine Well{\o}v} and Morten Schou and Lars Videbaek and Ida Gustafsson and Allan Flyvbjerg and Henrik Wiggers and Lise Tarnow",
note = "{\circledC} 2016 The Authors. European Journal of Heart Failure {\circledC} 2016 European Society of Cardiology.",
year = "2017",
doi = "10.1002/ejhf.657",
language = "English",
volume = "19",
pages = "69--77",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Wiley",
number = "1",

}

RIS

TY - JOUR

T1 - Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

AU - Jorsal, Anders

AU - Kistorp, Caroline

AU - Holmager, Pernille

AU - Tougaard, Rasmus Stilling

AU - Nielsen, Roni

AU - Hänselmann, Anja

AU - Nilsson, Brian

AU - Møller, Jacob Eifer

AU - Hjort, Jakob

AU - Rasmussen, Jon B.

AU - Boesgaard, Trine Welløv

AU - Schou, Morten

AU - Videbaek, Lars

AU - Gustafsson, Ida

AU - Flyvbjerg, Allan

AU - Wiggers, Henrik

AU - Tarnow, Lise

N1 - © 2016 The Authors. European Journal of Heart Failure © 2016 European Society of Cardiology.

PY - 2017

Y1 - 2017

N2 - AIMS: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes.METHODS AND RESULTS: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was -0.8% (-2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04).CONCLUSION: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

AB - AIMS: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes.METHODS AND RESULTS: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was -0.8% (-2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04).CONCLUSION: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

U2 - 10.1002/ejhf.657

DO - 10.1002/ejhf.657

M3 - Journal article

VL - 19

SP - 69

EP - 77

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 1

ER -

ID: 49154599